Molecular Pharmacology Program
The Jan Grimm Lab
The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative approaches for cancer diagnostics and therapy. These approaches evaluate underlying biology and utilize nanotechnology, chemistry and physics interrogated with modern imaging methods. The lab focuses currently several avenues: (i) the utilization of nanoparticles for cancer therapy; (ii) novel imaging approaches such as Cerenkov and optoacoustic imaging and (iii) the biology of PSMA both in prostate cancer and neovasculature using a tumor-on-chip microfluidic chip system.
Quo Vadis, Molecular Imaging? Grimm J, Kiessling F, Pichler BJ. J Nucl Med. 2020 Oct;61(10):1428-1434. doi: 10.2967/jnumed.120.241984. Epub 2020 Aug 28. PMID: 32859706.
Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring.Pratt EC, Isaac E, Stater EP, Yang G, Ouerfelli O, Pillarsetty N, Grimm J. J Nucl Med. 2020 Dec;61(12):1845-1850. doi: 10.2967/jnumed.120.241901. Epub 2020 May 22. PMID: 32444378.
Jan Grimm, MD, PhD
- Radiologist and Nuclear Medicine physician Jan Grimm develops novel approaches for improved diagnosis, monitoring and therapy of prostate and other cancers.
- MD, University of Hamburg (Germany)
- PhD, University of Kiel (Germany)
- [email protected]
- Email Address
- Office Phone
- Download CV
- PDF File
- View physician profile
- Physician profile
- Training in Urology
- University of Koeln, Germany
- 2014- NIH Nagy New Investigator Award
- 2018- The American Society for Clinical Investigation (ASCI) Member
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jan Grimm discloses the following relationships and financial interests:
Society of Nuclear Medicine and Molecular Imaging
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.